Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 study of 1% glycopyrronium bromide cream in adolescents with severe primary axillary hyperhidrosis
2022-000922-46Phase 2Completed
- Sponsor
- Dr. August Wolff
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glycopyrronium in essential axillary hyperhidrosis and hyperhidrosis, sponsored by Dr. August Wolff. Primary endpoints: Safety and local tolerability of 1% glycopyrronium bromide cream, Systemic exposure to glycopyrronium bromide and 1 more. Started Aug 2022; status: completed.
02
Drugs
glycopyrronium
03
Conditions
essential axillary hyperhidrosishyperhidrosis
Beyond the preview
Go deeper on 2022-000922-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000922-46.